Valneva Sees Strong Six-Month Antibody Persistence in Kids
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a company specializing in vaccines, recently announced some promising results pertaining to the antibody persistence and safety profile of its chikungunya vaccine, IXCHIQ®. This report follows the Phase 2 clinical trial that examined the vaccine's performance in children aged one to eleven years. The study included 304 participants and was partially funded by the Coalition for Epidemic Preparedness Innovations (CEPI) with backing from the European Union.
Positive Results from Phase 2 Clinical Trial
The trial revealed that IXCHIQ® was well tolerated across various dose levels, a crucial factor as it aims to protect children against chikungunya virus (CHIKV). Initial data highlights that the antibody levels remained high after six months, demonstrating a more robust immune response with the full dose of the vaccine. This profile mirrors results previously seen in adolescents and adults, enhancing confidence in the vaccine's safety and effectiveness.
Robust Immune Response
After six months, the immune response in children who had received a full dose was recorded at an impressive 96.5% seroresponse rate at Day 180. The positivity of these results is especially relevant in light of the increasing risk of chikungunya, particularly in regions where the disease is spreading rapidly. The trial's findings suggest the full dose's efficacy may be appropriate for the upcoming pivotal Phase 3 trial, anticipated to start in early 2026.
Importance of Vaccine Accessibility
Chief Medical Officer Juan Carlos Jaramillo, M.D., emphasized the importance of a safe and effective chikungunya vaccine, especially for vulnerable populations in regions where chikungunya is endemic. With over one million reported chikungunya cases in Brazil alone from 2019 to 2024, the urgency for preventive measures, particularly vaccines accessible to all age groups, is clear. The ability to deliver long-term protection from a single shot holds promise for improved public health outcomes.
The Growing Threat of Chikungunya
Chikungunya is a mosquito-borne viral disease causing symptoms such as fever and debilitating joint pain. The virus has consistently been reported in numerous countries, and outbreaks continue to pose severe threats, particularly in Latin America and India. This persistence underscores the need for effective vaccine developments and public health strategies, given that current outbreaks are noted not only in Brazil and India but also on French islands like La Reunion.
Phase 2 Study Details
The Phase 2 clinical trial, designated VLA1553-221, was rigorously designed, involving multiple centers performing randomized, observer-blinded studies on the safety and immunogenicity of two dosage levels of the chikungunya vaccine. With this data firmly establishing the vaccine's efficiency, Valneva is strategically poised to advance into pivotal trials, furthering the hope of combating this insidious disease.
Valneva's Vision and Future Outlook
At Valneva, the commitment to developing vaccines that cater to unmet medical needs remains steadfast. Their portfolio not only encompasses the much-anticipated chikungunya vaccine but also includes advanced candidates addressing Lyme disease, Zika, and more. This diverse pipeline showcases Valneva's expertise and dedication towards innovative health solutions.
Frequently Asked Questions
What is the primary focus of the Phase 2 trial conducted by Valneva?
The Phase 2 trial was aimed at evaluating the safety and immunogenicity of the chikungunya vaccine, IXCHIQ®, in children aged one to eleven.
How effective was the vaccine in terms of antibody persistence?
The vaccine showed a seroresponse rate of 96.5% at Day 180 post-vaccination, indicating strong antibody persistence.
Who funded the trial, and what was its significance?
The trial was partially funded by the Coalition for Epidemic Preparedness Innovations (CEPI) with support from the European Union, highlighting its importance in addressing public health needs.
When is the pivotal Phase 3 trial expected to begin?
The pivotal Phase 3 trial is expected to start in the first quarter of 2026.
What other vaccines is Valneva working on?
In addition to IXCHIQ®, Valneva is advancing vaccines for Lyme disease, Zika, and other notable infectious diseases.
